Hello,

I recently came across your commentary on the function of dipeptidyl peptidase 4 (DPP-4), its possible role in coronavirus infection, and your hypothesis that DPP-4 inhibition may play a role in severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) treatment [@b0005]. As my role is in surgery, acute systemic inflammation in people with type two diabetes is always on my mind to improve perioperative glycaemia and outcomes. I wanted to add to your discussion based on my experience in this field.

Endogenous cortisol, catecholamines and Interleukin-6 (IL-6) are main drivers in the post-operative stress response, causing acute insulin resistance and resulting in hyperglycemia in people with diabetes [@b0010]. This effect is so dramatic after cardiac surgery that up to 80% of people develop hyperglycemia regardless of diabetes status [@b0015]. Post-operative IL-6 increase has shown to cause glucacon like peptide 1 (GLP-1) release [@b0020], and pre-operative GLP-1 analogue administration has shown efficacy in reducing post-operative hyperglycemia brought on by cardiac and non cardiac surgery [@b0025], [@b0030], including superiority compared to pre-operative long acting insulin [@b0035]. Unfortunately, DPP-4 inhibitors have yet to show the same degree of success in this regard [@b0040], [@b0045].

As many people are likely taking GLP-1 analogues while mildly ill with SARS-COV-2, it may also be worthwhile studying the effects of GLP-1 analogues in preventing or reducing the sustained hyperglycemia resulting from systemic inflammation related to SARS-COV-2 infection. Based on their effectiveness in preventing and treating hyperglycemia related to systemic inflammation after cardiac and non-cardiac surgery, GLP-1 analogues may play an important future role here as well.

Thank you for your time, and stay well soon.
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